New Bolton Center Kennett Square, PA
Emergencies & Appointments:
Ryan Hospital Philadelphia, PA

Clinical Trial Using Immunotherapy For Dogs With Osteosarcoma

Mar 24, 2016

Please Note: Study Closed

Please note that we are no longer accepting registrants to this clinical trial. It has been closed.

Clinical Trial For Dogs With Osteosarcoma

Osteosarcoma is an aggressive cancer that frequently arises in the long bones of large-breed dogs. Approximately 90-95% of dogs with osteosarcoma have undetectable metastatic disease at presentation. Despite limb amputation and follow-up chemotherapy, most dogs are euthanized due to progressive metastatic disease within a year of diagnosis.

Dogs enrolled in this upcoming clinical trial will receive a HER2-targeting bacterial vaccine after amputation and chemotherapy. This immunotherapy has shown promising results in preventing metastatic disease when evaluated in a small number of dogs with osteosarcoma after surgery and chemotherapy.

Inclusion Criteria:

  • Dogs with a histopathological diagnosis of appendicular osteosarcoma
  • Dogs that have undergone limb amputation followed by 4-6 doses of carboplatin chemotherapy
  • Dogs that are otherwise healthy
  • Dogs that reside in PA, DE, NJ, MD, CT, NY, CA, AZ, or NV

Exclusion Criteria:

  • Evidence of metastatic disease at screening
  • Concurrent use of other chemotherapy or immunotherapy

 The study will pay for:

  • All visits and clinical and diagnostic tests associated with the clinical trial
  • Three doses of vaccine
  • Treatment of any side effects associated with the vaccine

The study does not pay for initial diagnostic tests, amputation, or chemotherapy.

Contact Information:

Dr. Nicola Mason